Long-term follow-up of a phase 2 trial of single agent lenalidomide in previously untreated patients with chronic lymphocytic leukaemia
- 24 February 2014
- journal article
- Published by Wiley in British Journal of Haematology
- Vol. 165 (5) , 731-733
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomideLeukemia, 2012
- Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemiaLeukemia & Lymphoma, 2011
- Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomideBlood, 2011
- Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemiaBlood, 2011
- Single-Agent Lenalidomide in the Treatment of Previously Untreated Chronic Lymphocytic LeukemiaJournal of Clinical Oncology, 2011
- Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trialThe Lancet, 2010
- Identification of a Primary Target of Thalidomide TeratogenicityScience, 2010
- Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemiaBlood, 2008
- Clinical Efficacy of Lenalidomide in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of a Phase II StudyJournal of Clinical Oncology, 2006